We looked inside some of the tweets by @PhRMA and here's what we found interesting.
Inside 100 Tweets
Did you know that hospitals are the primary drivers of health care spending? Conversations about health care spending need to look at the whole system. Read more: https://catalyst.phrma.org/fact-check-how-hospitals-continue-to-drive-health-care-spending
#DYK our very own researchers and labs in Massachusetts were featured in @PhRMA’s latest #GoBoldly video? We’re proud to represent the industry and medical innovation.
Watch Breakthrough here: http://bit.ly/2ZlPZzU
A hospital charged over $2800 for a rabies medicine that costs $350 at the pharmacy. Medicines don’t perform 8x better at the hospital, so why are patients billed 8x more? https://khn.org/news/a-brush-with-a-notorious-cat-my-rabies-education-and-the-big-bill-that-followed/
DYK that on top of the increasing role of retail pharmacies, specialty pharmacies owned by PBMs have also started aggressively contracting with 340B hospitals for their own financial benefit? https://catalyst.phrma.org/340b-spotlight-how-for-profit-middlemen-are-taking-advantage-of-a-program-meant-to-support-nonprofit-entities-and-patients
New analysis highlights how government intervention in Part B could threaten patient access to medicines https://catalyst.phrma.org/new-analysis-government-intervention-in-part-b-threatens-patient-access-to-medicines
Regardless of whether PBMs pass through rebates to insurers, the bottom line is that they aren’t being used to lower patients costs at the pharmacy counter. Read more: https://catalyst.phrma.org/three-things-to-know-about-the-part-d-gao-report
AARP continues to side with insurers over its own members when it comes to sharing savings with seniors. So it begs the question: Who is AARP really fighting for? Visit http://bit.ly/2KCqdmQ .
86% of AARP members support sharing the savings with seniors. But insurers don’t, and AARP is choosing to stand with them over its own members. So who is AARP really fighting for? http://bit.ly/2H78LVp
John O’Brien of @HHSGov has worked tirelessly to improve access and affordability for patients. I want to thank him for his leadership and thoughtful approach to finding the right solutions for our health care system.
Importing drugs, whether from Canada or elsewhere in the world, poses a huge safety risk. That’s why PhRMA and a number of other stakeholders are speaking out against the Administration’s drug importation proposal. https://catalyst.phrma.org/what-theyre-saying-safety-is-top-concern-for-recent-drug-importation-proposal
In today’s IP Explained blog we examine the four key forms of patents protections and how each plans an important and unique role in supporting innovation throughout the biopharmaceutical lifecycle. https://catalyst.phrma.org/ip-explained-how-patents-support-innovation-throughout-the-biopharmaceutical-lifecycle
.@DrugChannels & @RxTrace, on state importation laws: State legislators seem dangerously ill-informed about their states’ troubled history of counterfeit drugs. They're also recreating the chaos that preceded passage of a national track & trace system. http://bit.ly/2KqGlqa
Our Canadian neighbors have been clear about the fact they have no interest in becoming the medicine cabinet for the United States. More here: https://catalyst.phrma.org/icymi-canadian-government-stakeholders-voice-concerns-with-drug-importation-proposals
A must read from Bloomberg sets the record straight on why importing drugs from Canada won’t work. https://www.bloomberg.com/news/articles/2019-08-01/trump-s-crazy-drug-import-plan-stirs-supply-fears-in-canada via @business
The Admin’s importation scheme is dangerous. No way to guarantee safety of drugs that come into the US. Rather than surrender the safety of Americans, we need solutions that would lower patient costs at the pharmacy. https://www.phrma.org/press-release/phrma-statement-on-administration-s-drug-importation-scheme
Policy and health care leaders including CEO @steveubl recently joined @TheAtlantic to discuss the rising cost burden on seniors and solutions that help them access the medicines they need without harming the next generation of Medicare beneficiaries: http://bit.ly/2KdSkax
Latest figures demonstrate #biopharma commitment translating basic science to R&D for innovative new medicines. In 2017, the entire industry invested $97 billion in an ecosystem that works for patients https://catalyst.phrma.org/ip-explained-understanding-biopharmaceutical-innovation by @AndrewPowaleny
Check out PhRMA CEO @SteveUbl’s op-ed in the @StarTribune on what the biopharma industry is doing to help diabetes patients. http://www.startribune.com/drug-makers-are-trying-to-help-diabetes-patients/512965122/
In our final session at Innovation Day, speaking with Vas Narasimhan of @Novartis, @dramyabernethy notes there is "momentum" in development and use of real-world evidence and highlights @US_FDA already making use of it for aiding in review. #GoBoldly